RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Andrew Taylor to Diabetes Mellitus, Type 2

This is a "connection" page, showing publications Andrew Taylor has written about Diabetes Mellitus, Type 2.
Connection Strength

0.807
  1. Cohen ND, Gutman SJ, Briganti EM, Taylor AJ. Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study. Intern Med J. 2019 08; 49(8):1006-1010.
    View in: PubMed
    Score: 0.400
  2. Toledo FG, Taylor A. Alternative site testing at the earlobe tip: reliability of glucose measurements and pain perception. Diabetes Care. 2004 Feb; 27(2):616-7.
    View in: PubMed
    Score: 0.137
  3. Walford GA, Colomo N, Todd JN, Billings LK, Fernandez M, Chamarthi B, Warner AS, Davis J, Littleton KR, Hernandez AM, Fanelli RR, Lanier A, Barbato C, Ackerman RJ, Khan SQ, Bui R, Garber L, Stolerman ES, Moore AF, Huang C, Kaur V, Harden M, Taylor A, Chen L, Manning AK, Huang P, Wexler D, McCarthy RM, Lo J, Thomas MK, Grant RW, Goldfine A, Hudson MS, Florez JC. The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes. PLoS One. 2015; 10(3):e0121553.
    View in: PubMed
    Score: 0.074
  4. Billings LK, Jablonski KA, Ackerman RJ, Taylor A, Fanelli RR, McAteer JB, Guiducci C, Delahanty LM, Dabelea D, Kahn SE, Franks PW, Hanson RL, Maruthur NM, Shuldiner AR, Mayer-Davis EJ, Knowler WC, Florez JC. The influence of rare genetic variation in SLC30A8 on diabetes incidence and ?-cell function. J Clin Endocrinol Metab. 2014 May; 99(5):E926-30.
    View in: PubMed
    Score: 0.068
  5. Walford GA, Davis J, Warner AS, Ackerman RJ, Billings LK, Chamarthi B, Fanelli RR, Hernandez AM, Huang C, Khan SQ, Littleton KR, Lo J, McCarthy RM, Rhee EP, Deik A, Stolerman E, Taylor A, Hudson MS, Wang TJ, Altshuler D, Grant RW, Clish CB, Gerszten RE, Florez JC. Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitus. Metabolism. 2013 Dec; 62(12):1772-8.
    View in: PubMed
    Score: 0.066
  6. Pollin TI, Isakova T, Jablonski KA, de Bakker PI, Taylor A, McAteer J, Pan Q, Horton ES, Delahanty LM, Altshuler D, Shuldiner AR, Goldberg RB, Florez JC, Franks PW. Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program. PLoS Genet. 2012; 8(8):e1002895.
    View in: PubMed
    Score: 0.062
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support